Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 81

Humanity in 2050

👉For business inquiries: [email protected].
✅ Instagram: https://www.instagram.com/pro_robots.

In the quest to overcome the limitations of the human body and mind, scientists worldwide are diligently working on various technologies. The question arises: What will human beings become after undergoing numerous enhancements? Will we retain our identity while embracing the possibilities offered by artificial intelligence? What extraordinary capabilities will biotechnology bestow upon us? And how will our emotions and desires evolve as our bodies undergo transformation?

Join us on a captivating journey to the year 2050, as we delve into the frontiers of scientific research, consult with visionary futurists, and examine the predictions of brilliant minds. Together, we will explore the profound changes that lie ahead!

00.00 — Introduction.
01:15 — Matrix-Like Innovation: Baby-Growing Factories Bring Science Fiction to Reality.
02:33 — The Future of Longevity: Exploring Eternal Youth Technologies.
03:51 — Unlocking Superpowers: Genetic Engineering Takes Humans and Animals to New Heights!
05:11 — Brain Implants in 2050: The Future of Communication, Control, and Enhanced Human Abilities.

Redefining Human Life.
In the year 2050, the human body will undergo a transformation like never before. For the first time in our 300,000-year history, evolution will not solely rely on natural selection but rather on deliberate re-engineering through technology.

Revolutionary Childbirth.

Continue reading “Humanity in 2050” | >

With first-in-human trial results, Intellia shows the world that gene editing has arrived

All medical breakthroughs have to start somewhere, and Intellia Therapeutics is ready to show the world the first-in-human gene editing data that could be the start of a | Interim results are in for Intellia and partner Regeneron’s in vivo CRISPR/Cas9 genome editing candidate, NTLA-2001, in patients with transthyretin (ATTR) amyloidosis: and the numbers look good. This is the first time gene editing has been proven to work in humans, which “opens up a whole new area of therapies for patients that wasn’t there.”

Nano-mechanoelectrical approach increases DNA detection sensitivity by 100 times

UMass Amherst researchers have pushed forward the boundaries of biomedical engineering one hundredfold with a new method for DNA detection with unprecedented sensitivity.

“DNA detection is in the center of bioengineering,” says Jinglei Ping, lead author of the paper that appeared in Proceedings of the National Academy of Sciences.

Ping is an assistant professor of mechanical and , an adjunct assistant professor in and affiliated with the Center for Personalized Health Monitoring of the Institute for Applied Life Sciences. “Everyone wants to detect the DNA at a low concentration with a high sensitivity. And we just developed this method to improve the sensitivity by about 100 times with no cost.”

Dr. Alex Colville, Ph.D. — Co-Founder and General Partner — age1

Venture Investing To Catalyze The Next Generation Of Founder-Led, Longevity Biotech Companies — Dr. Alex Colville, Ph.D., Co-Founder and General Partner — age1.

Dr. Alex Colville, Ph.D. is Co-Founder and General Partner of age1 (https://age1.com/), a venture capital firm focused on catalyzing the next generation of founder-led, longevity biotech companies, with a strategy of building a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related diseases.

With a recent initial closing of US$35 million, age1 will be focusing on founders and companies at the earliest stages of first-money in, pre-seed and seed funding, and is resourced to continue to support companies through later rounds.

Dr. Colville previously established the biotech arm of Starbloom Capital and served as founding Chief of Staff of Amaranth Foundation, where he led: the foundation’s support of skilled researchers and ambitious moonshot projects in the longevity field, and helped to advance their lobbying efforts; the TIME Initiative (a group with mission to activate undergraduate students’ interest in aging biology); the Marine Biology Laboratory Biology of Aging Summer Course, among other programs.

Dr. Colville completed his Ph.D. in Genetics at Stanford University studying the biology of aging in Dr. Thomas Rando’s lab while consulting for several family offices, the R&D team of Rubedo Life Sciences, and the business development team of Maze Therapeutics. Prior to his Ph.D., while at Northeastern University completing his Bachelor of Science (B.S.) in Chemical Engineering with a Minor in Biochemical Engineering, he advised pharma companies as a management consultant at Putnam Associates, a boutique life sciences consulting firm.

Continue reading “Dr. Alex Colville, Ph.D. — Co-Founder and General Partner — age1” | >

“Inverse vaccine” shows potential to treat multiple sclerosis and other autoimmune diseases

A typical vaccine teaches the human immune system to recognize a virus or bacteria as an enemy that should be attacked. The new “inverse vaccine” does just the opposite: it removes the immune system’s memory of one molecule. While such immune memory erasure would be unwanted for infectious diseases, it can stop autoimmune reactions like those seen in multiple sclerosis, type I diabetes, or rheumatoid arthritis, in which the immune system attacks a person’s healthy tissues.

The inverse vaccine, described in Nature Biomedical Engineering, takes advantage of how the liver naturally marks molecules from broken-down cells with “do not attack” flags to prevent autoimmune reactions to cells that die by natural processes. PME researchers coupled an antigen — a molecule being attacked by the immune system— with a molecule resembling a fragment of an aged cell that the liver would recognize as friend, rather than foe. The team showed how the vaccine could successfully stop the autoimmune reaction associated with a multiple-sclerosis-like disease.

“In the past, we showed that we could use this approach to prevent autoimmunity,” said Jeffrey Hubbell, the Eugene Bell Professor in Tissue Engineering and lead author of the new paper. “But what is so exciting about this work is that we have shown that we can treat diseases like multiple sclerosis after there is already ongoing inflammation, which is more useful in a real-world context.”

Longevity Summit Dublin

The last 2 questions and the answers are great. The first starts at 30 minutes. And I like his answer to the 2nd question especially, the time is 33:54. “What is giving me great hope is that we’re entering the phases where we have more than enough tools to get really get close to escape velocity.”

Genome Engineering for Healthy Longevity – George Church at Longevity Summit Dublin 2023.

#GeorgeChurch #GenomeEngineering #HealthyLongevity #LongevitySummitDublin2023 #AgingResearch #DublinConference #LongevityScience #BiomedicalEngineering #GeneticModification #DublinTalks #GenomicInnovation #MedicalScience #LongevityResearch #PrecisionMedicine #AgingInterventions #Healthspan #GenomeEditing #AntiAging #LongevityInsights #Genetics #Innovation

Examining the genesis of CRISPR’s molecular scissors

Genome engineering may be the future of medicine, but it relies on evolutionary advances made billions of years ago in primordial bacteria, the original masters of gene editing.

Modern day genome engineers like Columbia’s Sam Sternberg are always looking forward, modifying these ancient systems and pushing them to perform ever more complex feats of gene editing.

But to uncover , it sometimes pays to look backward in time to understand how bacteria first created the original systems, and why.

Newly engineered CRISPR enzyme for editing DNA could improve patient treatment

A new CRISPR-based gene-editing tool has been developed which could lead to better treatments for patients with genetic disorders. The tool is an enzyme, AsCas12f, which has been modified to offer the same effectiveness but at one-third the size of the Cas9 enzyme commonly used for gene editing. The compact size means that more of it can be packed into carrier viruses and delivered into living cells, making it more efficient.

Researchers created a library of possible AsCas12f mutations and then combined selected ones to engineer an AsCas12f with 10 times more editing ability than the original unmutated type. This engineered AsCas12f has already been successfully tested in mice and has the potential to be used for new, more effective treatments for patients in the future.

By now you have probably heard of CRISPR, the gene-editing tool which enables researchers to replace and alter segments of DNA. Like genetic tailors, scientists have been experimenting with “snipping away” the genes that make mosquitoes malaria carriers, altering food crops to be more nutritious and delicious, and in recent years begun to overcome some of the most challenging diseases and genetic disorders.

Science Fiction Meets Neuro-Reality: Organoids to Rebuild the Brain

This is leading to even better brain engineering 👏 🙌 👌 😀 😄.

Computer-augmented brains, cures to blindness, and rebuilding the brain after injury all sound like science fiction. Today, these disruptive technologies aren’t just for Netflix, “Terminator,” and comic book fodder — in recent years, these advances are closer to reality than some might realize, and they have the ability to revolutionize neurological care.

Neurologic disease is now the world’s leading cause of disability, and upwards of 11 million people have some form of permanent neurological problem from traumatic brain injuries and stroke. For example, if a traumatic brain injury has damaged the motor cortex — the region of the brain involved in voluntary movements — patients could become paralyzed, without hope of regaining full function. Or some stroke patients can suffer from aphasia, the inability to speak or understand language, due to damage to the brain regions that control speech and language comprehension.

Thanks to recent advances, sometimes lasting neurologic disease can be prevented. For example, if a stroke patient is seen quickly enough, life-threatening or-altering damage can be avoided, but it’s not always possible. Current treatments to most neurologic disease are fairly limited, as most therapies, including medications, aim to improve symptoms but can’t completely recover lost brain function.

ChatGPT: Will It Transform the World of Health Care?

The recent introduction of the breathtaking AI tool ChatGPT has sparked a national dialogue about the future of artificial intelligence in health care, education, research, and beyond. In this session, four UCSF experts discuss AI’s current and potential uses, in areas ranging from research to education to clinical care. After a brief presentation by each speaker, DOM Chair Bob Wachter moderates a far-ranging panel discussion on the health care applications of ChatGPT.

Speakers:
Atul Butte, MD, PhD, professor of Pediatrics, Bioengineering and Therapeutic Sciences, and Epidemiology and Biostatistics; director, UCSF Bakar Computational Health Sciences Institute; chief data scientist, University of California Health System.

Daniel Lowenstein, MD, professor of Neurology; former executive vice chancellor and provost, UCSF

Sara Murray, MD, MAS, associate professor, Division of Hospital Medicine at UCSF Health; associate chief medical information officer, Inpatient Care and Data Science, UCSF Health.

Aaron Neinstein, MD, associate professor, Division of Endocrinology at UCSF Health; vice president of Digital Health, UCSF Health; senior director, UCSF Center for Digital Health Innovation.

Note: Closed captions will be available within 48–72 hours after posting.

Continue reading “ChatGPT: Will It Transform the World of Health Care?” | >
/* */